

This document applies to the following:

Formulary	Applies
Standard Control (SF)	☐
Standard Control Choice (SCCF)	☐
Preferred Drug Plan Design (PDPD)	☐
Advanced Control Specialty (ACSF)	☐
Advanced Control Specialty Choice (ACSCF)	☐
Managed Medicaid Template (MMT)	☐
Marketplace (MF)	☒
Aetna Small Group Affordable Care Act (SG ACA)	☒
Aetna Health Exchange (AHE)	☒
Value (VF)	☐

Formulary	Applies
New to Market (NTM)	☐
Standard Formulary Chart (SFC)	☐
Basic Control Chart Preferred Drug Plan Design (BCC PDPD)	☐
Advanced Control Specialty Formulary Chart (ACSCF)	☐
Value Formulary Chart (VFC)	☐
Medical Benefit	☐
Medical Benefit: Advanced Biosimilars First	☐
Combined Benefit Management (CBM)	☐
Combined Benefit Management Pharmacy (CBMP)	☐
Medical Benefit Managed Medicaid (MMMB)	☐

Exceptions Criteria

Acromegaly Products

This document informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

These criteria were developed to align with the following: Marketplace Formulary (MF), and Aetna Small Group Affordable Care Act (SG ACA), Aetna Health Exchange (AHE).

Plan Design Summary

This program applies to the acromegaly products specified in this document. Coverage for a targeted product is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with a targeted product.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Acromegaly Products

Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

	Products
Preferred	• octreotide acetate injection • Somatuline Depot (lanreotide) • Somavert (pegvisomant)
Targeted	• Bynfezia Pen (octreotide acetate) • Mycapssa (octreotide acetate delayed-release capsules) • octreotide acetate for injectable suspension • Palsonify (paltusotine) • Sandostatin LAR (octreotide acetate for injectable suspension) • Signifor LAR (pasireotide)

Exception Criteria

This program applies to members requesting treatment for an indication that is FDA-approved for all of the preferred products.

Coverage for a targeted product is provided when the member has a documented inadequate response or intolerable adverse event with any of the preferred products.

References

1. Somatuline Depot [package insert]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; July 2024.
2. Somavert [package insert]. New York, NY: Pharmacia & Upjohn Co; July 2023.
3. Bynfezia Pen [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries Ltd.; February 2025.
4. Mycapssa [package insert]. Needham, MA: Chiasma, Inc.; August 2024.
5. Sandostatin LAR Depot [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2024.
6. Signifor LAR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Company; July 2024.
7. Octreotide acetate for injectable suspension. Parsippany, NJ: Teva Pharmaceuticals; January 2024.
8. Octreotide acetate for injectable solution [package insert]. Morgantown, WV 26505: Mylan Institutional LLC; July 2024.
9. Palsonify [package insert]. San Diego, CA: Crinetics Pharmaceuticals, Inc.; September 2025.